Ibrutinib is a medication used in this clinical trial. It is designed to help treat certain types of blood cancers by blocking a specific protein that helps cancer cells grow and divide. The trial aims to gather long-term safety and effectiveness data for patients who have been receiving this medication and continue to benefit from it.

B-cell non-Hodgkin’s lymphoma – This is a type of cancer that originates in the lymphatic system, specifically affecting B-lymphocytes, which are a type of white blood cell. It typically presents as painless swelling of lymph nodes, but can also affect other organs. The disease can progress at varying rates, with some forms being slow-growing and others more aggressive. As it advances, it may lead to symptoms such as fever, night sweats, and unexplained weight loss. The progression can involve the spread of cancerous cells to other parts of the body, including the bone marrow and spleen.

Chronic graft-versus-host disease (cGVHD) – This condition occurs when donor cells attack the recipient’s body following a stem cell or bone marrow transplant. It can affect multiple organs, including the skin, liver, and digestive tract. Symptoms may include skin rashes, dry mouth, and liver dysfunction. The disease can develop months after the transplant and may persist for a long time. It often leads to chronic inflammation and tissue damage in the affected areas. The progression can vary widely, with some individuals experiencing mild symptoms and others facing more severe complications.